Is there still a room for crizotinib in first-line setting in ALK-positive NSCLC patients?

How to increase crizotinib into the brain?

Crizotinib is a P-gp substrate.

Zhang – Lancet Oncol 2015 * Costa – JCO 2011 *Tang – int J Cancer 2014

Elacridar is a P-gp inhibitor

Elacridar + crizotinib enhanced the intracranial

accumulation of crizotinib at 24 h by 70 times.

Crizotinib CSF/plasma ratio: 0.0026